Table 1 Clinical characteristics of patients included in the study (n=47)
From: Hippocampal sclerosis in women with temporal lobe epilepsy: seizure and pregnancy outcomes
Variable | Mean(±SD)/Value(rate) |
|---|---|
Age at pregnancy mean (SD) | 25.7 (3.0) |
Educational years (n, %) | |
< 9 year | 17 (36.1%) |
9–12 year | 11 (23.4%) |
> 12 year | 19 (40.4%) |
Seizure freedom in the preconceptional year | 9 (19.1%) |
Duration of epilepsy in years (median, IQR) | 9.0 (7.0-12.0) |
FBTCS frequency in the periconceptional year | |
None | 31 (66.0%) |
Yearly | 8 (17.0%) |
Quarterly | 4 (8.4%) |
Monthly | 3 (6.4%) |
Weekly | 1 (2.1%) |
FIAS frequency in the periconceptional year (n, %) | |
None | 15 (31.9%) |
Yearly | 4 (8.5%) |
Quarterly | 3 (6.4%) |
Monthly | 17 (36.2%) |
Weekly | 4 (8.5%) |
Daily | 1 (2.1%) |
Multiple times per day | 3 (6.4%) |
ASM administration before pregnancy (n, %) | |
LEV | 14 (29.8%) |
LTG | 12 (25.5%) |
CBZ | 9 (19.1%) |
TPM | 8 (17.0%) |
VPA | 8 (17.0%) |
Seizure exacerbation during pregnancy (n, %) | 19 (40.4%) |
Seizure freedom during pregnancy (n, %) | 16 (34.0%) |
Seizure occurrence in the postpartum week (n, %)b | 7 (20.0%) |
Number of ASMs during pregnancy (n, %) | |
None | 11 (23.4%) |
One | 21 (41.7%) |
More than one | 15 (31.9%) |
ASMs administration during pregnancy (n, %) | |
LEV | 18 (38.3%) |
LTG | 13 (27.7%) |
CBZ | 9 (19.1%) |
TPM | 4 (8.5%) |
VPA | 3 (6.4%) |
ASM adherence during pregnancy (n, %)b | 29 (67.4%)a |
ASMs adjustment (n, %) | 14 (32.6%)a |
Fetal loss (n, %) | |
Spontaneous abortion | 3 (6.4%) |
Induced abortion | 9 (19.1%) |
Cesarean section (n, %)a | 27 (77.1%)b |
Birth weight < 2.5kg, (n, %)a | 3 (8.6%)b |
Apgar scores (< 7) (n, %) | 0 (0.0%) |
Major congenital malformations (n, %) | 0 (0.0%) |